CJC-1295/Ipamorelin

• Stimulate the anterior pituitary via GHRH receptor binding (CJC-1295 No DAC) to trigger release of stored GH
• Amplify GH pulse amplitude when a GHRH analog is paired with a GHS such as Ipamorelin
• Produce a quick GH spike due to the short half life profile of MOD-GRF (1-29), avoiding sustained GH elevation seen with DAC based analogs
• Support a more physiologic secretion pattern by emphasizing pulses rather than prolonged elevation

Research involving this combination explores

• Lean mass support and body composition related endpoints through GH pulse amplification
• Fat metabolism support signals via GH mediated substrate utilization effects
• Recovery and tissue repair related signaling, including connective tissue and joint support endpoints
• Collagen synthesis related signals that may support skin elasticity and wound healing models
• Metabolic health endpoints, including glucose regulation and energy balance related measures

This formulation approach is often described as generally well tolerated in research settings, with potential observations including: Because CJC-1295 (No DAC) is designed to mimic pulsatile secretion, it is commonly framed as having a lower desensitization risk than long acting GH analog approaches.

• Mild transient flushing
• Temporary injection site irritation such as mild redness or swelling
• Short lived GH related adjustment effects such as temporary water retention or numbness that resolve as the model adapts

• CJC No DAC and Ipamorelin act on different receptors, allowing synergy
• No published negative interactions between the two in research models
• Should only be handled in controlled laboratory settings